Sinobioway Cell Therapy is developing chimeric antigen receptor T-cell technology based immunotherapies for cancer cure. Sinobioway is affiliated with Peking University.
Sinobioway Cell Therapy is subsidary of Sinobioway Group. Founded in 1992,Sinobioway Group is affiliated with Peking University and headquartered in the 20-heactare Peking University Biocity, which houses companys administration and R&D operations.
Sinobioway has collaborated with Baylor College of Medicine to introduce the chimeric antigen receptor (CAR) T-cell therapy technology.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
In May 2015, Sinobioway and BioAtla LLC entered into a strategic collaboration for the development and commercialization of select Conditionally Active Biologic (CAB) antibodies and other CAB-based therapeutics in China. BioAtla received $19 Mn in program payments and equity investment from Sinobioway as part of a total of more than $70 Mn in payments and investment from Sinobioway over the next 12 months. Sinobioway received the exclusive rights to develop and commercialize selected CAB antibodies in China.
Recover your password.
A password will be e-mailed to you.